Home
Dashboard
Info
Curated content
Blue Economy Guide
Blue Companies
Oceans and Sea Basins
Blue Finance
Blue Igniters
AspBAN
Investment heatmap
Matching tool
Companies
Arxx Therapeutics
Save
Arxx Therapeutics
Develops a first-in-class monoclonal antibody with a unique mechanism of action targeting non-resolving tissue fibrosis.
Launch date
2019
Employees
2-10 people
Company register number
815295242
Oslo Norway (HQ)
View more
https://arxxtx.com/
https://www.linkedin.com/company/arxx-therapeutics/
B2B
manufacturing
commission
health
biotechnology
hard tech
biotechnology
Overview
Similar companies
Investments (1)
Analytics
Notes
Job openings
Innovations (0)
Patents (2)
Arxx Therapeutics funding
Arxx Therapeutics investors
Edit
Date
Investors
Amount
Round
-
ShareLab
p53 Invest
Sarsia
N/A
-
Nov 2020
Innovation Norway
NOK3.2m
Grant
Jan 2024
*
Oxitope Pharma
N/A
Merger
Total Funding
$387k
Recent News about Arxx Therapeutics
Edit
Investments by Arxx Therapeutics
Edit
Oxitope Pharma